Our findings reinforce the prognostic significance of SMAD4 in CRC, suggesting its utility for refining risk stratification and informing targeted therapeutic strategies for high‐risk patients, including TGF‐β pathway inhibitors or immunotherapies. This evidence concerns the gene SMAD4 and colorectal carcinoma.